CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Enoxaparin Prefilled Syringe [Lovenox]drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04354155
NCT04354155Phase 2Completed
CompareCT.gov

COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial

Johns Hopkins All Children's Hospital·interventional·Posted Apr 21, 2020·Updated Oct 12, 2022

In Brief

A Phase 2 clinical trial evaluating Enoxaparin Prefilled Syringe [Lovenox] for Infection Viral and 2 related conditions. Completed, enrolled 40 participants across 16 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, dose-requirements, and exploratory efficacy of twice-daily subcutaneous enoxaparin as venous thromboembolism prophylaxis in children (birth to 18 years) hospitalized with signs and/or symptoms of SARS-CoV-2 infection (i.e., COVID-19).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfection Viral, Thromboses, Venous, COVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 21, 2020
Enrollment StartJun 2, 2020
Primary CompletionJun 4, 2021
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 6.2 years ago

Interventions

Enoxaparin Prefilled Syringe [Lovenox]drug

Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)